London: In an analyst report revealed on Wednesday morning, Numis maintained their Add rating on shares of Burford Capital Ltd (LON:BUR). They currently have a GBX 1200.00 target price per share on the firm. Numis’s target means a potential downside of -12.47% from the company’s stock close price.
Imprimis Pharmaceuticals, Inc. engages in the development, production, and sale of medications to physicians and patients in the United States. The company has market cap of $40.52 million. The Company’s ophthalmology program consists of Dropless Therapy injectable and LessDrops topical formulations. It currently has negative earnings. The firm also offers a conscious sedation medication, the IV Free MKO Melt, an alternative to intravenous sedation.
The stock decreased 1.52% or $0.03 during the last trading session, reaching $1.95. About 73,751 shares traded. Imprimis Pharmaceuticals, Inc. (IMMY) has declined 2.70% since March 14, 2017 and is downtrending. It has underperformed by 19.40% the S&P500.
Marathon Asset Management Lp holds 0.14% of its portfolio in Imprimis Pharmaceuticals, Inc. for 792,434 shares. Berson & Corrado Investment Advisors Llc owns 123,119 shares or 0.11% of their US portfolio. Moreover, Bard Associates Inc has 0.05% invested in the company for 60,700 shares. The California-based Granite Investment Partners Llc has invested 0.01% in the stock. Ardsley Advisory Partners, a Connecticut-based fund reported 20,000 shares.
Among 7 analysts covering Burford Capital Ltd (LON:BUR), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Burford Capital Ltd has GBX 1322 highest and GBX 237 lowest target. GBX 1138.17’s average target is -16.92% below currents GBX 1370 stock price. Burford Capital Ltd had 43 analyst reports since January 4, 2016 according to SRatingsIntel. As per Monday, January 4, the company rating was maintained by N+1 Singer. The rating was maintained by N+1 Singer with “Buy” on Tuesday, January 3. The stock of Burford Capital Limited (LON:BUR) earned “Buy” rating by Liberum Capital on Tuesday, June 13. Numis Securities upgraded the shares of BUR in report on Wednesday, December 14 to “Buy” rating. The company was maintained on Thursday, July 27 by Liberum Capital. The company was maintained on Monday, January 9 by Numis Securities. Macquarie Research maintained the shares of BUR in report on Wednesday, June 14 with “Outperform” rating. The company was maintained on Tuesday, March 14 by Numis Securities. The rating was maintained by Liberum Capital on Tuesday, March 13 with “Hold”. The firm earned “Add” rating on Tuesday, June 13 by Numis Securities.